Percutaneous mitral valve replacement: First steps

Original Title: Percutaneous Transvenous Transseptal Transcatheter Valve Implantation in Failed Bioprosthetic Mitral Valves, Ring Annuloplasty, and Severe Mitral Annular Calcification. Reference: Eleid MF et al. JACC Cardiovasc Interv. 2016 Jun 13;9(11):1161-74.   Courtesy of Dr. Agustín Vecchia.   Transfemoral percutaneous transvenous mitral valve implantation is a promising technique and, despite the fact that no devices<a href="https://solaci.org/en/2016/06/16/percutaneous-mitral-valve-replacement-first-steps/" title="Read more" >...</a>

Bons resultados clínicos após implante transcateter da prótese valvar mitral Edwards Fortis®

Fundamentos: A regurgitação mitral severa (MR) representa a segunda doença cardíaca valvar mais prevalente nos países ocidentais. De um terço a metade dos pacientes que necessitam de reparo da valva mitral / substituição são considerados de muito alto risco para cirurgia. O procedimento percutâneo mitral de reparo de borda a borda surgiu como uma alternativa<a href="https://solaci.org/en/2015/06/24/bons-resultados-clinicos-apos-implante-transcateter-da-protese-valvar-mitral-edwards-fortis-2/" title="Read more" >...</a>

Bons resultados nos procedimentos de implante transcateter valva-em-valva mitral e valva-em-anel mitral

Fundamentos: Válvulas bioprotéticas são cada vez mais implantadas em cirurgias cardíacas abertas. Estas válvulas geralmente falham, resultando na necessidade de uma nova cirurgia cardíaca, com risco elevado de mortalidade. O implante transcateter valva-em-valva mitral (VIVM) pode eliminar a necessidade de reoperação. A implantação transcateter valva-em-valva e valva-em-anel mitral (VIAM) é uma abordagem menos invasiva e,<a href="https://solaci.org/en/2015/06/24/bons-resultados-nos-procedimentos-de-implante-transcateter-valva-em-valva-mitral-e-valva-em-anel-mitral-2/" title="Read more" >...</a>

Safety and efficacy of Cardiobrand device for percutaneous mitral annuloplasty

The Cadiobrand device is implanted through a transseptal approach and makes a reduction in the mitral annulus area. The study included 24 patients with moderate mitral regurgitation (functional class III- IV) and high surgical risk. The device was successfully implanted in all cases reducing the annular size by 92 % and to the same extent<a href="https://solaci.org/en/2015/06/24/safety-and-efficacy-of-cardiobrand-device-for-percutaneous-mitral-annuloplasty/" title="Read more" >...</a>

Third generation percutaneous aortic valve in intermediate-risk patients

Original title: Multicenter Evaluation of a Next-Generation Balloon-Expandable Transcatheter Aortic Valve. Reference: John Webb, et al. J Am Coll Cardiol 2014;64:2235-43 Percutaneous aortic valve replacement is starting to be a reasonable alternative in patients at intermediate risk. One hundred and fifty patients who received SAPIEN 3rd generation percutaneous aortic valve implantation were analyzed prospectively. The STS score of<a href="https://solaci.org/en/2015/01/02/third-generation-percutaneous-aortic-valve-in-intermediate-risk-patients/" title="Read more" >...</a>

Similar mortality outcomes with MitraClip and surgery in high risk patients with severe mitral valve regurgitation

Original title: Survival of transcatheter mitral valve repair compared with surgical and conservative treatment in high-surgical-risk patients. Reference: Swaans MJ et al.  J Am CollCardiolIntv. 2014;7:875-881. In high-surgical-risk patients with symptomatic severe mitral valve regurgitation, MitraClip for transcatheter mitral valve repair and surgery showed similar survival rates in addition to superiority when compared to standard medical treatment. This<a href="https://solaci.org/en/2014/08/30/similar-mortality-outcomes-with-mitraclip-and-surgery-in-high-risk-patients-with-severe-mitral-valve-regurgitation/" title="Read more" >...</a>

Implanting a second valve and embolization are two complications that increase mortality

Original title: Determinats and Outcomes of Acute transcatheter Valve-in Valve Therapy or Embolization. Reference: Raj R Makkar, et al. J Am Coll Cardiol 2013;62:418-30   Percutaneous aortic valve implantation has proven to be feasible, safe and a successful follow up. Only in a few patients is the two-valve implantation necessary due to bad positioning or embolism but<a href="https://solaci.org/en/2013/08/06/implanting-a-second-valve-and-embolization-are-two-complications-that-increase-mortality/" title="Read more" >...</a>

Aortic Transfemoral Valve Replacement using Edwards SAPIEN and Edwards SAPIEN XT Prosthesis, Local Anesthesia.

Reference: Durand E. et al (JACC CV interventions 2012 in press)1 When percutaneous aortic valve replacement (AVR) first began the procedure required a large-bore sheath (22-24 F), being the most frequent surgical strategy when using general anesthesia. Continuous technological advances achieved the miniaturization of devices which allow the procedure to be performed with a much<a href="https://solaci.org/en/2012/10/01/aortic-transfemoral-valve-replacement-using-edwards-sapien-and-edwards-sapien-xt-prosthesis-local-anesthesia/" title="Read more" >...</a>

ATC guiada por iFR ¿es igual en la DA que en el resto de los vasos?

Predictors of DCB Failure in De Novo Lesions

Percutaneous coronary intervention (PCI) with drug coated balloons (DCB) is a viable alternative, especially in patients at high risk of bleeding, side-branch lesions in coronary bifurcation, or in small coronary segments. De novo heart disease treated with DCB has been shown non-inferior to conventional DES stenting, according to the PICCOLETO-II trial.  However, these interventions are<a href="https://solaci.org/en/2024/07/08/predictors-of-dcb-failure-in-de-novo-lesions-2/" title="Read more" >...</a>

Resultados a 2 años del balón farmacológico Lutonix sobre la femoral superficial

Biolimus vs Paclitaxel Coated Balloons for the Treatment of In-Stent Restenosis

Drug eluting stent (DES) in-stent restenosis (ISR) is currently a challenging, seeing as it often requires repeat revascularization. The use of drug coated balloons (DCB) offers the advantage of delivering the drug without the need for re-stenting. This highlights the importance of the technological development of DCB, with diverse drug formulations and coating technologies. As<a href="https://solaci.org/en/2024/07/02/biolimus-vs-paclitaxel-coated-balloons-for-the-treatment-of-in-stent-restenosis/" title="Read more" >...</a>